Brief: Vera Therapeutics Acquires Global Rights To Novel, Next Generation Dual Baff/April Inhibitor
13/01/2025 13:39
Jan 13 (Reuters) - Vera Therapeutics Inc VERA.O :
* VERA THERAPEUTICS ACQUIRES GLOBAL RIGHTS TO NOVEL, NEXT
GENERATION DUAL BAFF/APRIL INHIBITOR
* TO DEVELOP AND MARKET VT-109 WITH UNDISCLOSED PAYMENTS
Source text: ID:nGNX253pgS
Further company coverage: VERA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Vera Therapeutics
See all newsU.S. STOCKS ON THE MOVE-Forgent Power, Vera Bradley, Wells Fargo
U.S. STOCKS ON THE MOVE-Forgent Power, Vera Bradley, Wells Fargo
U.S. STOCKS ON THE MOVE-Eli Lilly, Waystar, Wells Fargo
U.S. STOCKS ON THE MOVE-Eli Lilly, Waystar, Sysco
Vera Therapeutics gains after kidney disease drug meets goals in confirmatory trial